08:37 AM EDT, 09/16/2025 (MT Newswires) -- Adagene ( ADAG ) said Tuesday that it has amended its existing collaboration and license agreement with biotech company Exelixis ( EXEL ) .

The amended terms allow Exelixis ( EXEL ) to use Adagene's ( ADAG ) SAFEbody technology platform to generate a masked monoclonal antibody for the development of an antibody-drug conjugate against an Exelixis ( EXEL )-nominated solid tumor target, Adagene ( ADAG ) said.

Adagene ( ADAG ) said it is eligible to receive development and commercialization milestones and royalties on net sales of products developed around that target.

Shares of Adagene ( ADAG ) were up 11% in recent Tuesday premarket activity.